CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: VERTIGO TREATMENT MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Peripheral Vertigo
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Central Vertigo
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
CHAPTER 5: VERTIGO TREATMENT MARKET, BY TREATMENT
5.1 Overview
5.1.1 Market size and forecast
5.2 Anticholinergics
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Antihistamines
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Others
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
CHAPTER 6: VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital Pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Drug Stores & Retail Pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.3.4 Drug Stores & Retail Pharmacies Vertigo Treatment Market by Prescription Type
6.3.4.1 Prescription Drugs Market size and forecast, by region
6.3.4.2 OTC Drugs Market size and forecast, by region
6.4 Online Providers
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: VERTIGO TREATMENT MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Type
7.2.3 North America Market size and forecast, by Treatment
7.2.4 North America Market size and forecast, by Distribution channel
7.2.4.1 North America Drug Stores & Retail Pharmacies Vertigo Treatment Market by Prescription Type
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Type
7.2.5.1.2 Market size and forecast, by Treatment
7.2.5.1.3 Market size and forecast, by Distribution channel
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Type
7.2.5.2.2 Market size and forecast, by Treatment
7.2.5.2.3 Market size and forecast, by Distribution channel
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Type
7.2.5.3.2 Market size and forecast, by Treatment
7.2.5.3.3 Market size and forecast, by Distribution channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Type
7.3.3 Europe Market size and forecast, by Treatment
7.3.4 Europe Market size and forecast, by Distribution channel
7.3.4.1 Europe Drug Stores & Retail Pharmacies Vertigo Treatment Market by Prescription Type
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Type
7.3.5.1.2 Market size and forecast, by Treatment
7.3.5.1.3 Market size and forecast, by Distribution channel
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Type
7.3.5.2.2 Market size and forecast, by Treatment
7.3.5.2.3 Market size and forecast, by Distribution channel
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Type
7.3.5.3.2 Market size and forecast, by Treatment
7.3.5.3.3 Market size and forecast, by Distribution channel
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Type
7.3.5.4.2 Market size and forecast, by Treatment
7.3.5.4.3 Market size and forecast, by Distribution channel
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Type
7.3.5.5.2 Market size and forecast, by Treatment
7.3.5.5.3 Market size and forecast, by Distribution channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Type
7.3.5.6.2 Market size and forecast, by Treatment
7.3.5.6.3 Market size and forecast, by Distribution channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Type
7.4.3 Asia-Pacific Market size and forecast, by Treatment
7.4.4 Asia-Pacific Market size and forecast, by Distribution channel
7.4.4.1 Asia-Pacific Drug Stores & Retail Pharmacies Vertigo Treatment Market by Prescription Type
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Type
7.4.5.1.2 Market size and forecast, by Treatment
7.4.5.1.3 Market size and forecast, by Distribution channel
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Type
7.4.5.2.2 Market size and forecast, by Treatment
7.4.5.2.3 Market size and forecast, by Distribution channel
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Type
7.4.5.3.2 Market size and forecast, by Treatment
7.4.5.3.3 Market size and forecast, by Distribution channel
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Type
7.4.5.4.2 Market size and forecast, by Treatment
7.4.5.4.3 Market size and forecast, by Distribution channel
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Type
7.4.5.5.2 Market size and forecast, by Treatment
7.4.5.5.3 Market size and forecast, by Distribution channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Type
7.4.5.6.2 Market size and forecast, by Treatment
7.4.5.6.3 Market size and forecast, by Distribution channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Type
7.5.3 LAMEA Market size and forecast, by Treatment
7.5.4 LAMEA Market size and forecast, by Distribution channel
7.5.4.1 LAMEA Drug Stores & Retail Pharmacies Vertigo Treatment Market by Prescription Type
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Type
7.5.5.1.2 Market size and forecast, by Treatment
7.5.5.1.3 Market size and forecast, by Distribution channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Type
7.5.5.2.2 Market size and forecast, by Treatment
7.5.5.2.3 Market size and forecast, by Distribution channel
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Type
7.5.5.3.2 Market size and forecast, by Treatment
7.5.5.3.3 Market size and forecast, by Distribution channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Type
7.5.5.4.2 Market size and forecast, by Treatment
7.5.5.4.3 Market size and forecast, by Distribution channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 AstraZeneca plc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Endo Pharmaceuticals Inc
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Epic Pharma, LLC
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 GlaxoSmithKline plc.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Hoffmann-La Roche
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Novartis AG
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Pfizer Inc.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Sanofi
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Sun Pharmaceutical Industries Ltd.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Teva Pharmaceutical Ltd.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
9.11 Viatris (Mylan N.V.)
9.11.1 Company overview
9.11.2 Company snapshot
9.11.3 Operating business segments
9.11.4 Product portfolio
9.11.5 Business performance
9.11.6 Key strategic moves and developments
9.12 Zydus Cadila
9.12.1 Company overview
9.12.2 Company snapshot
9.12.3 Operating business segments
9.12.4 Product portfolio
9.12.5 Business performance
9.12.6 Key strategic moves and developments
TABLE 1. GLOBAL VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 2. VERTIGO TREATMENT MARKET SIZE, FOR PERIPHERAL VERTIGO, BY REGION, 2021-2031 ($MILLION)
TABLE 3. VERTIGO TREATMENT MARKET FOR PERIPHERAL VERTIGO, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. VERTIGO TREATMENT MARKET SIZE, FOR CENTRAL VERTIGO, BY REGION, 2021-2031 ($MILLION)
TABLE 5. VERTIGO TREATMENT MARKET FOR CENTRAL VERTIGO, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. GLOBAL VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 7. VERTIGO TREATMENT MARKET SIZE, FOR ANTICHOLINERGICS, BY REGION, 2021-2031 ($MILLION)
TABLE 8. VERTIGO TREATMENT MARKET FOR ANTICHOLINERGICS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 9. VERTIGO TREATMENT MARKET SIZE, FOR ANTIHISTAMINES, BY REGION, 2021-2031 ($MILLION)
TABLE 10. VERTIGO TREATMENT MARKET FOR ANTIHISTAMINES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 11. VERTIGO TREATMENT MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 12. VERTIGO TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 13. GLOBAL VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 14. VERTIGO TREATMENT MARKET SIZE, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 15. VERTIGO TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 16. VERTIGO TREATMENT MARKET SIZE, FOR DRUG STORES & RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 17. VERTIGO TREATMENT MARKET FOR DRUG STORES & RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 18. GLOBAL DRUG STORES & RETAIL PHARMACIES VERTIGO TREATMENT MARKET, BY PRESCRIPTION TYPE, 2021-2031 ($MILLION)
TABLE 19. VERTIGO TREATMENT MARKET, FOR PRESCRIPTION DRUGS, BY REGION, 2021-2031 ($MILLION)
TABLE 20. VERTIGO TREATMENT MARKET, FOR OTC DRUGS, BY REGION, 2021-2031 ($MILLION)
TABLE 21. VERTIGO TREATMENT MARKET SIZE, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
TABLE 22. VERTIGO TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 23. VERTIGO TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 24. NORTH AMERICA VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 25. NORTH AMERICA VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 26. NORTH AMERICA VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 27. NORTH AMERICA DRUG STORES & RETAIL PHARMACIES VERTIGO TREATMENT MARKET, BY PRESCRIPTION TYPE, 2021-2031 ($MILLION)
TABLE 28. NORTH AMERICA VERTIGO TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 29. U.S. VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 30. U.S. VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 31. U.S. VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 32. CANADA VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 33. CANADA VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 34. CANADA VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 35. MEXICO VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 36. MEXICO VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 37. MEXICO VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 38. EUROPE VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 39. EUROPE VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 40. EUROPE VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 41. EUROPE DRUG STORES & RETAIL PHARMACIES VERTIGO TREATMENT MARKET, BY PRESCRIPTION TYPE, 2021-2031 ($MILLION)
TABLE 42. EUROPE VERTIGO TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 43. GERMANY VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 44. GERMANY VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 45. GERMANY VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 46. FRANCE VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 47. FRANCE VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 48. FRANCE VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 49. UK VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 50. UK VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 51. UK VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 52. ITALY VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 53. ITALY VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 54. ITALY VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 55. SPAIN VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 56. SPAIN VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 57. SPAIN VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 58. REST OF EUROPE VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 59. REST OF EUROPE VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 60. REST OF EUROPE VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 61. ASIA-PACIFIC VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 62. ASIA-PACIFIC VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 63. ASIA-PACIFIC VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 64. ASIA-PACIFIC DRUG STORES & RETAIL PHARMACIES VERTIGO TREATMENT MARKET, BY PRESCRIPTION TYPE, 2021-2031 ($MILLION)
TABLE 65. ASIA-PACIFIC VERTIGO TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 66. JAPAN VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 67. JAPAN VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 68. JAPAN VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 69. CHINA VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 70. CHINA VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 71. CHINA VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 72. AUSTRALIA VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 73. AUSTRALIA VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 74. AUSTRALIA VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 75. INDIA VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 76. INDIA VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 77. INDIA VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 78. SOUTH KOREA VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 79. SOUTH KOREA VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 80. SOUTH KOREA VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 81. REST OF ASIA-PACIFIC VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 82. REST OF ASIA-PACIFIC VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 83. REST OF ASIA-PACIFIC VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 84. LAMEA VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 85. LAMEA VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 86. LAMEA VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 87. LAMEA DRUG STORES & RETAIL PHARMACIES VERTIGO TREATMENT MARKET, BY PRESCRIPTION TYPE, 2021-2031 ($MILLION)
TABLE 88. LAMEA VERTIGO TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 89. BRAZIL VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 90. BRAZIL VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 91. BRAZIL VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 92. SAUDI ARABIA VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 93. SAUDI ARABIA VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 94. SAUDI ARABIA VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 95. SOUTH AFRICA VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 96. SOUTH AFRICA VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 97. SOUTH AFRICA VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 98. REST OF LAMEA VERTIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 99. REST OF LAMEA VERTIGO TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 100. REST OF LAMEA VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 101.ASTRAZENECA PLC.: COMPANY SNAPSHOT
TABLE 102.ASTRAZENECA PLC.: OPERATING SEGMENTS
TABLE 103.ASTRAZENECA PLC.: PRODUCT PORTFOLIO
TABLE 104.ASTRAZENECA PLC.: NET SALES,
TABLE 105.ASTRAZENECA PLC.: KEY STRATERGIES
TABLE 106.ENDO PHARMACEUTICALS INC: COMPANY SNAPSHOT
TABLE 107.ENDO PHARMACEUTICALS INC: OPERATING SEGMENTS
TABLE 108.ENDO PHARMACEUTICALS INC: PRODUCT PORTFOLIO
TABLE 109.ENDO PHARMACEUTICALS INC: NET SALES,
TABLE 110.ENDO PHARMACEUTICALS INC: KEY STRATERGIES
TABLE 111.EPIC PHARMA, LLC: COMPANY SNAPSHOT
TABLE 112.EPIC PHARMA, LLC: OPERATING SEGMENTS
TABLE 113.EPIC PHARMA, LLC: PRODUCT PORTFOLIO
TABLE 114.EPIC PHARMA, LLC: NET SALES,
TABLE 115.EPIC PHARMA, LLC: KEY STRATERGIES
TABLE 116.GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
TABLE 117.GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
TABLE 118.GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
TABLE 119.GLAXOSMITHKLINE PLC.: NET SALES,
TABLE 120.GLAXOSMITHKLINE PLC.: KEY STRATERGIES
TABLE 121.HOFFMANN-LA ROCHE: COMPANY SNAPSHOT
TABLE 122.HOFFMANN-LA ROCHE: OPERATING SEGMENTS
TABLE 123.HOFFMANN-LA ROCHE: PRODUCT PORTFOLIO
TABLE 124.HOFFMANN-LA ROCHE: NET SALES,
TABLE 125.HOFFMANN-LA ROCHE: KEY STRATERGIES
TABLE 126.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 127.NOVARTIS AG: OPERATING SEGMENTS
TABLE 128.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 129.NOVARTIS AG: NET SALES,
TABLE 130.NOVARTIS AG: KEY STRATERGIES
TABLE 131.PFIZER INC.: COMPANY SNAPSHOT
TABLE 132.PFIZER INC.: OPERATING SEGMENTS
TABLE 133.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 134.PFIZER INC.: NET SALES,
TABLE 135.PFIZER INC.: KEY STRATERGIES
TABLE 136.SANOFI: COMPANY SNAPSHOT
TABLE 137.SANOFI: OPERATING SEGMENTS
TABLE 138.SANOFI: PRODUCT PORTFOLIO
TABLE 139.SANOFI: NET SALES,
TABLE 140.SANOFI: KEY STRATERGIES
TABLE 141.SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 142.SUN PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
TABLE 143.SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 144.SUN PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,
TABLE 145.SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
TABLE 146.TEVA PHARMACEUTICAL LTD.: COMPANY SNAPSHOT
TABLE 147.TEVA PHARMACEUTICAL LTD.: OPERATING SEGMENTS
TABLE 148.TEVA PHARMACEUTICAL LTD.: PRODUCT PORTFOLIO
TABLE 149.TEVA PHARMACEUTICAL LTD.: NET SALES,
TABLE 150.TEVA PHARMACEUTICAL LTD.: KEY STRATERGIES
TABLE 151.VIATRIS (MYLAN N.V.): COMPANY SNAPSHOT
TABLE 152.VIATRIS (MYLAN N.V.): OPERATING SEGMENTS
TABLE 153.VIATRIS (MYLAN N.V.): PRODUCT PORTFOLIO
TABLE 154.VIATRIS (MYLAN N.V.): NET SALES,
TABLE 155.VIATRIS (MYLAN N.V.): KEY STRATERGIES
TABLE 156.ZYDUS CADILA: COMPANY SNAPSHOT
TABLE 157.ZYDUS CADILA: OPERATING SEGMENTS
TABLE 158.ZYDUS CADILA: PRODUCT PORTFOLIO
TABLE 159.ZYDUS CADILA: NET SALES,
TABLE 160.ZYDUS CADILA: KEY STRATERGIES
| ※参考情報 めまい治療は、平衡感覚の異常によって引き起こされる症状に対する医療行為です。めまいは、自分自身や周囲の環境が回転していると感じたり、ふらふらする感覚を伴います。この症状は、内耳や神経系の異常に起因することが多く、様々な原因が考えられます。したがって、治療方法も原因によって異なり、多岐にわたります。 めまいは、大きく分けて二つのタイプに分類されます。まず一つ目は、回転性めまいであり、耳石や内耳の異常が原因となっていることが多いです。これには、良性発作性頭位めまい症（BPPV）、メニエール病、内耳炎などが含まれます。回転性めまいは、頭の動きに伴って感じることが多く、日常生活に大きな影響を及ぼすことがあります。 二つ目は、非回転性めまいです。このタイプのめまいは、様々な要因から生じることが多く、脳の疾患や心因性の問題などが考えられます。たとえば、脳卒中や偏頭痛、抑うつ状態によるものが該当します。非回転性めまいは、個々の患者によって感じ方や持続時間が異なることが特徴です。 めまい治療には、薬物療法、リハビリテーション、手術などが含まれます。薬物療法としては、抗めまい薬や抗ヒスタミン薬が一般的に使用されます。これにより、めまいの症状を軽減し、患者が日常生活を送る上での苦痛を和らげることができます。また、内耳の異常が原因である場合には、利尿剤が処方されることもあります。これにより、内耳の液体バランスを調整し、症状を緩和する効果が期待されます。 リハビリテーションは、特に良性発作性頭位めまい症に効果的です。平衡訓練を行うことで、めまいを引き起こす要因に対する体の適応力を高めることができます。特に、エプリー法と呼ばれる手法は、耳石が内耳から外れるのを助ける方法として知られています。この手技を行うことで、めまいを軽減することが可能です。 手術は、他の治療法が効果を発揮しない場合に選択されます。たとえば、メニエール病の患者には、内耳の手術を行うことで、症状を根本的に改善することが試みられることがあります。また、内耳の神経を切除する手術も行われますが、これにはリスクが伴うため、慎重な判断が求められます。 さらに、最近では新しい関連技術が開発されています。たとえば、バランススケールを用いた測定により、患者のバランス機能を評価することができます。これにより、治療方針をより個別化することが可能となります。また、VR（仮想現実）を用いたリハビリテーションも注目されており、患者が現実世界ではない環境で平衡訓練を行うことができるようになっています。これにより、めまい症状に対する適応が早まると期待されています。 総じて、めまい治療には多様な手法が存在し、それぞれの患者の症状や原因に応じて適切なアプローチが求められます。専門医の診断を受け、個別に最適な治療法を見つけることが重要です。生活の質を向上させるために、めまいに対する正しい理解と適切な治療が欠かせません。現在でも研究が進められており、新たな治療法の開発や改善が期待されています。これにより、今後のめまい治療がより効果的かつ安全なものとなることが望まれます。 |
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
